Invest now
Beta Drugs share price
- ₹2,478.90(1.62%)July 21, 2026 15:29:54 PM IST
- NSE
- BSE
- Vol : 51.16 K (NSE + BSE)Last 20 day avg : 64.27 K
Beta Drugs is trading 1.62% upper at Rs 2,478.90 as compared to its last closing price. Beta Drugs has been trading in the price range of 2,495.40 & 2,383.90. Beta Drugs has given 57.47% in this year & 3.90% in the last 5 days. Beta Drugs has TTM P/E ratio 26.50 as compared to the sector P/E of 25.57.Listed peers of Beta Drugs include Sun Pharmaceutical Industries (0.30%), Divi's Laboratories (0.14%), Torrent Pharmaceuticals (0.71%).The Mutual Fund holding in Beta Drugs was at -% in . The MF holding has - from the last quarter. The FII holding in Beta Drugs was at 1.02% in 30 Jun 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 21 Jul 2026, 10:52 PM IST
- BetaLow volatility0.66Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.60The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/BIn line with historical values10.10The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values54.36Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates overvaluation5.24The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Beta Drugs News
Beta Drugs Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,962.15 | 0.30 | 4,70,774.42 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 7,332.20 | 0.14 | 1,94,646.87 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 5,038.75 | 0.71 | 1,70,587.40 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,432.65 | -0.61 | 1,15,735.96 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,143.10 | -0.31 | 1,13,929.21 | 21.19 | 4.24 | 0.09 | 14.22 |
Beta Drugs Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-07-20 | Quarterly Results |
| 2026-05-14 | Audited Results |
| 2026-02-14 | Quarterly Results |
| 2026-01-09 | Others |
| 2025-11-06 | Quarterly Results |
About the company Beta Drugs
- IndustryBiotechnology & Drugs
- ISININE351Y01019
- BSE Code
- NSE CodeBETA
Beta Drugs Limited is an India-based oncology medicine manufacturing company. The Company specializes in the intricate field of complex chemical synthesis for anti-cancer bulk drugs and finished dosages. The Company operates through one segment, Pharmaceuticals. Its product category includes cosmeceutical products and oncology products. The cosmeceutical products include La’Thrix, BACINOX, URTICALM, HUMIDA, NUSPLASH, UVIREX, ADVIBE, SENSIBAR, and RECAPRO. The oncology products include Temozad(Temozolomide), ADVIN(Vinorelbine), ADSIDE(Etoposide), ADRIB(Doxorubicin), ADCOV(Leucovorin calcium), ADPLATIN(Oxaliplatin), INOTAD(Irinotecan), ADCIST(Cisplatin), ADCARB(Carboplatin), ERLOTAD(Erlotinib), ADOXI(Docetaxel), AMGICIN(Gemcitabine), ADPAXIL(Paclitaxel), ADMIDE(Bicalutamide), and others. The Company's subsidiaries include Adley Lab Limited and Adley Formulations Private Limited.
Beta Drugs Share Price FAQs
Beta Drugs is trading at 2478.90 as on Tue Jul 21 2026 09:59:54. This is 1.62% upper as compared to its previous closing price of 2439.40.
The market capitalization of Beta Drugs is 2512.83 Cr as on Tue Jul 21 2026 09:59:54.
The 52 wk high for Beta Drugs is 2674.00 whereas the 52 wk low is 990.10
Beta Drugs can be analyzed on the following key metrics -
- TTM P/E: 26.50
- Sector P/E: 25.57
- Dividend Yield: 0.00%
- D/E ratio: 0.60
Beta Drugs reported a net profit of 41.48 Cr in 2026.
Quick Links
EQUITY QUICK LINKS
Beta Drugs QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.